Top

Published in:

Open Access 01-04-2014 | Topic Paper

Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma

Authors: Olivier Cussenot, Karim Sighar, Mansoor Mohammed, Sylvain Hugonin, Valérie Ondet, Stéphane Larre, Roger Lacave, Morgan Roupret, Géraldine Cancel-Tassin

Published in: World Journal of Urology | Issue 2/2014

Abstract

Introduction

Bladder carcinoma (B-TCC) is the fifth most prevalent carcinoma in the United States (US) or Europe. In addition, B-TCC is the most expensive carcinoma per patient between diagnosis and death, because of its 50–80 % recurrence rate. B-TCC is an optimal carcinoma for which to detect DNA alterations in urine, which is easily obtainable. Chromosomal aberrations in tumors have been closely related to the carcinogenesis process.

Material and Methods

We developed a highly specific and sensitive oligo-CGH-array for the diagnosis and follow-up of B-TCC, based on the detection of chromosomal aberrations in urine samples. One hundred and sixty-four urine samples were analyzed. The qualitative results, including chromosomal aberrations, were obtained. Quantitative results are expressed as a percentage of chromosomal alterations on the autosomes.

Results

From the urine samples, we were able to differentiate B-TCC from non-malignant conditions with an accuracy of 100 % for patients without history of B-TCC. For follow-up of B-TCC in clinical practice, at least a deletion (8p; 9p; 9q) or a cut-off of >2 % of chromosomal imbalance was considered as a positive test. According to our criteria, 100 % of high-grade tumors were diagnosed, and the sensitivity to predict positive cystoscopy was 95 % (specificity 73 %). A cut-off >9 % was a strong signature of high-grade TCC (odds ratio 53 CI 95 % 7–417; p = 0.0002).

Conclusion

We developed a sensitive clinical tool for the detection of B-TCC using DNA extracted from patient urine. This tool is also able to identify low-grade B-TCC and identify high-risk patients harboring a high-grade disease.

Green DA, Rink M, Cha EK, Xylinas E, Chughtai B, Scherr DS, Shariat SF, Lee RK (2013) Cost-effective treatment of low-risk carcinoma not invading bladder muscle. BJU Int 111(3 Pt B):78–84CrossRef

Schäfauer C, Ettori D, Rouprêt M, Phé V, Tualle JM, Tinet E, Avrillier S, Egrot C, Traxer O, Cussenot O (2013) Detection of bladder urothelial carcinoma using in vivo noncontact, ultraviolet excited autofluorescence measurements converted into simple color coded images: a feasibility study. J Urol 190(1):271–277. doi:10.1016/j.juro.2013.01.100 PubMedCrossRef

Stenzl A, Penkoff H, Dajc-Sommerer E, Zumbraegel A, Hoeltl L, Scholz M, Riedl C, Bugelnig J, Hobisch A, Burger M, Mikuz G, Pichlmeier U (2011) Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : a multicenter randomized, double-blind, placebo-controlled trial. Cancer 117(5):938–947PubMedCrossRef

Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB (2003) Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 95:588PubMedCrossRef

Zhang Y, Denton BT, Nielsen ME (2013) Comparison of surveillance strategies for low-risk bladder cancer patients. Med Decis Mak 33(2):198–214CrossRef

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, Rouprêt M (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59(6):997–1008PubMedCrossRef

Tomasini JM, Konety BR (2013) Urinarymarkers/cytology: what and when should a urologist use. Urol Clin North Am 40(2):165–173PubMedCrossRef

Cheng L, Zhang S, MacLennan GT, Williamson SR, Lopez-Beltran A, Montironi R (2011) Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 42(4):455–481PubMedCrossRef

Mao L, Schoenberg MP, Scicchitano M, Erozan YS, Merlo A, Schwab D, Sidransky D (1996) Molecular detection of primary bladder cancer by microsatellite analysis. Science 271(5249):659–662PubMedCrossRef

10.

Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, Jen J, Sidransky D (2000) Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287(5460):2017–2019PubMedCrossRef

11.

Hurst CD, Platt FM, Taylor CF, Knowles MA (2012) Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. Clin Cancer Res 18(21):5865–5877PubMedCrossRef

12.

Al Hussain TO, Akhtar M (2013) Molecular basis of urinary bladder cancer. Adv Anat Pathol 20(1):53–60PubMedCrossRef

13.

Veltman JA, Fridlyand J, Pejavar S, Olshen AB, Korkola JE, DeVries S, Carroll P, Kuo WL, Pinkel D, Albertson D, Cordon-Cardo C, Jain AN, Waldman FM (2003) Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 63(11):2872–2880PubMed

14.

Larré S, Camparo P, Comperat E, Gil Diez De Medina S, Traxer O, Roupret M, Sebe P, Cancel-Tassin G, Sighar K, Lozach F, Cussenot O (2011) Diagnostic, staging, and grading of urothelial carcinomas from urine: performance of BCA-1, a mini-array comparative genomic hybridisation-based test. Eur Urol 59(2):250–257

15.

Hoque MO, Lee J, Begum S, Yamashita K, Engles JM, Schoenberg M, Westra WH, Sidransky D (2003) High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Res 63(18):5723–5726PubMed

16.

Bulashevska S, Szakacs O, Brors B, Eils R, Kovacs G (2004) Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data. Int J Cancer 110(6):850–856PubMedCrossRef

17.

Chow NH, Cairns P, Eisenberger CF, Schoenberg MP, Taylor DC, Epstein JI, Sidransky D (2000) Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 89(6):514–518PubMedCrossRef

18.

Huysentruyt CJ, Baldewijns MM, Rüland AM, Tonk RJ, Vervoort PS, Smits KM, van de Beek C, Speel EJ (2011) Modified UroVysion scoring criteria increase the urothelial carcinoma detection rate in cases of equivocal urinary cytology. Histopathology 58(7):1048–1053PubMedCrossRef

19.

Panzeri E, Conconi D, Antolini L, Redaelli S, Valsecchi MG, Bovo G, Pallotti F, Viganò P, Strada G, Dalprà L, Bentivegna A (2011) Chromosomal aberrations in bladder cancer: fresh versus formalin fixed paraffin embedded tissue and targeted FISH versus wide microarray-based CGH analysis. PLoS ONE 6(9):e24237PubMedCentralPubMedCrossRef

20.

Chekaluk Y, Wu CL, Rosenberg J, Riester M, Dai Q, Lin S, Guo Y, McDougal WS, Kwiatkowski DJ (2013) Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. PLoS ONE 8(4):e60927PubMedCentralPubMedCrossRef

21.

Noël N, Couteau J, Maillet G, Gobet F, d’Aloisio F, Minier C, Pfister C (2013) Preliminary study of p53 and FGFR3 gene mutations in the urine for bladder tumors. Prog Urol 23(1):29–35PubMedCrossRef

22.

Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE 5(11):e13821PubMedCentralPubMedCrossRef

23.

van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, Zwarthoff EC (2005) A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 11:7743–7748PubMedCrossRef

24.

Maitra A, Cohen Y, Gillespie SE, Mambo E, Fukushima N, Hoque MO, Shah N, Goggins M, Califano J, Sidransky D, Chakravarti A (2004) The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res 14(5):812–819PubMedCentralPubMedCrossRef

Title: Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma
Authors: Olivier Cussenot
Karim Sighar
Mansoor Mohammed
Sylvain Hugonin
Valérie Ondet
Stéphane Larre
Roger Lacave
Morgan Roupret
Géraldine Cancel-Tassin
Publication date: 01-04-2014
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 2/2014
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-013-1191-3

At a glance: The STEP trials

Springer Medicine

Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma

Abstract

Introduction

Material and Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Material and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2014

Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer

A systematic review of the treatment for female stress urinary incontinence by ACT® balloon placement (Uromedica, Irvine, CA, USA)

Impact of international variation of prostate cancer on a predictive nomogram for biochemical recurrence in clinically localised prostate cancer

Comparison of post-operative intravesical recurrence and oncological outcomes after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma

Expression of β-tubulin isotypes in urothelial carcinoma of the bladder

Prostate biopsy: results and advantages of the transperineal approach—twenty-year experience of a single center